Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lund University Hospital
With
Valcuria
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-80 years
Histologically confirmed (according to the WHO classification) diffuse large B-cell lymphoma stage II-IV
No previous treatment for lymphoma. Corticosteroids for alleviation of lymphoma associated symptoms are allowed
WHO performance status 0-2
HIV negativity
Seronegativity for HCV, HBsAg, anti-HBc, or other active infection uncontrolled by treatment
Absence of psychiatric illness or condition which could interfere with the subjects ability understand the requirements of the study
Absence of neurological or neuropsychiatric disorder, interfering with the requirements of the study
Absence of hearing impairment \> grade 2
Absence of porphyria
In females: absence of pregnancy and lactation
All subjects must agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy
All subjects must agree not to share study medication with another person, and to return all unused study drug to investigators
Written informed concent according to ICH/GCP and Swedish regulations
Clareo Health | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
